Celldex Therapeutics Inc (NASDAQ:CLDX) price on Wednesday, February 05, rose 3.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $23.99.
A look at the stock’s price movement, the close in the last trading session was $23.15, moving within a range at $23.14 and $24.34. The beta value (5-Year monthly) was 1.594. Turning to its 52-week performance, $53.18 and $22.17 were the 52-week high and 52-week low respectively. Overall, CLDX moved -10.52% over the past month.
Celldex Therapeutics Inc’s market cap currently stands at around $1.59 billion, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -68.37% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 6.83M, representing a -0.78% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CLDX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CLDX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CLDX’s current price about -1.56% and -5.82% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.67, while 7-day volatility ratio is 5.33% and 6.05% in the 30-day chart. Further, Celldex Therapeutics Inc (CLDX) has a beta value of 1.73, and an average true range (ATR) of 1.35. Analysts have given the company’s stock an average 52-week price target of $62, forecast between a low of $44 and high of $80. Looking at the price targets, the low is -83.41% off current price level while to achieve the yearly target high, price needs to move -233.47%. Nonetheless, investors will most likely welcome a -158.44% jump to $62 which is the analysts’ median price.
If we refocus on Celldex Therapeutics Inc (NASDAQ:CLDX), historical trading data shows that trading volumes averaged 0.81 over the past 10 days and 1.03 million over the past 3 months. The company’s latest data on shares outstanding shows there are 66.34 million shares.
The 2.48% of Celldex Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 105.04% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 8.48 million on 2025-01-15, giving us a short ratio of 7.86. The data shows that as of 2025-01-15 short interest in Celldex Therapeutics Inc (CLDX) stood at 1478.0 of shares outstanding, with shares short rising to 7.31 million registered in 2024-12-13. Current price change has pushed the stock -5.07% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CLDX stock continues to rise going into the next quarter.
